Patty joined EyeBio as VP, Regulatory CMC in March 2024. She is responsible for overseeing global CMC filing strategies and submissions and has over 35 years of pharmaceutical experience in big pharma and small biotech specializing in Chemistry, Manufacturing & Controls (CMC).
Patty began her career at Merck and after 17 years of working in the labs and moving into Regulatory, moved on to several small biotech companies where she progressed to the level of Vice President. She is well versed with all aspects of regulatory guidelines and submissions from original clinical trial applications through new drug applications and commercial product deletions. She is proficient in defining global CMC strategies and led Regulatory Affairs CMC for three start-up companies including Pharmasset, IVERIC Bio, and Oyster Point Pharma.
Patty received her B.S. in chemistry from Seton Hall University and a M.S. in analytical chemistry from the University of Massachusetts, Amherst.
